A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors

Delta-like protein 3 (DLL3) is highly expressed in solid tumors, including neuroendocrine carcinomas/neuroendocrine tumors (NEC/NET). Rovalpituzumab tesirine (Rova-T) is a DLL3-targeting antibody-drug conjugate. Patients with NECs and other advanced DLL3-expressing tumors were enrolled in this phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Mansfield, Aaron S., Hong, David S., Hann, Christine L., Farago, Anna F., Beltran, Himisha, Waqar, Saiama N., Hendifar, Andrew E., Anthony, Lowell B., Taylor, Matthew H., Bryce, Alan H., Tagawa, Scott T., Lewis, Karl, Niu, Jiaxin, Chung, Christine H., Cleary, James M., Rossi, Michael, Ludwig, Carrianne, Valenzuela, Ricardo, Luo, Yan, Aggarwal, Rahul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342450/
https://www.ncbi.nlm.nih.gov/pubmed/34354225
http://dx.doi.org/10.1038/s41698-021-00214-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342450/
https://www.ncbi.nlm.nih.gov/pubmed/34354225
http://dx.doi.org/10.1038/s41698-021-00214-y

Ejemplares similares